Forest Laboratories, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Forest Laboratories, Inc.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Carbogen Amcis, LGM Pharma, Vetter and PCI Pharma are focusing on expanding their businesses, while ChemWerth has filed its 500th drug master file for clevidipine with the FDA.
- Other Names / Subsidiaries
- Aptalis Pharma Inc. (Axcan Pharma, Inc.
- Eurand N.V.
- Mpex Pharmaceuticals, Inc.)
- Cerexa, Inc.
- Clinical Data, Inc.